Related Experiment Video
Updated: Feb 6, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
Encorafenib and Binimetinib: First Global Approvals
1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
Encorafenib and binimetinib, targeting BRAF and MEK pathways respectively, are approved for advanced melanoma with specific mutations. This combination therapy offers a new treatment option for patients with BRAF-mutation-positive unresectable or metastatic melanoma.
Area of Science:
- Oncology
- Pharmacology
Background:
- Encorafenib is a BRAF inhibitor, and binimetinib is a MEK inhibitor.
- Both are orally bioavailable drugs developed by Array BioPharma.
Purpose of the Study:
- To summarize the development milestones of encorafenib and binimetinib.
- To highlight their first global approvals for treating specific melanoma types.
Main Methods:
- Review of drug development and regulatory submission data.
- Summary of clinical development phases and approvals.
Main Results:
- Encorafenib and binimetinib received US FDA approval in June 2018 for combination use.
- Applications submitted in EU, Australia, Switzerland, and Japan; positive opinion from EMA in July 2018.
- Combination therapy is also in Phase III trials for metastatic colorectal cancer.
Conclusions:
- Encorafenib and binimetinib combination therapy represents a significant advancement in treating BRAF-mutation-positive advanced melanoma.
- The development journey highlights successful targeted therapy drug discovery and approval processes.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Global Climate Change
Introduction to Global Positioning System
Errors in Global Positioning System
Global Regulatory Systems
Field Application of Global Positioning System

